DNK-651-3
Phase 2
- Conditions
- Prevention of influenza infection
- Registration Number
- JPRN-jRCT2080223664
- Lead Sponsor
- DENKA SEIKEN CO.,LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Japanese over 13 years old
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does DNK-651 utilize to prevent influenza infection in Japanese patients over 13 years old?
How does DNK-651 compare to standard-of-care influenza vaccines in terms of immunogenicity and safety in phase II trials?
Are there specific biomarkers identified in the JPRN-jRCT2080223664 trial that correlate with enhanced immune response to DNK-651?
What adverse events were reported in the JPRN-jRCT2080223664 phase II trial and what management strategies were employed?
What related compounds or combination therapies is DENKA SEIKEN CO.,LTD. developing alongside DNK-651 for influenza prevention?